Another recommendation: Variability among risk classification models β perform the same at a population level, but very differently for individuals. https://t.co/BcKkzk7bW1 #RadAIchat
Good study: Many studies have generalizability and bias issues, but in general AI + Human seems to be the most effective combination. https://t.co/i1UotCPbTt #RadAIchat
Important study to be aware of: RCT in Sweden on AI in screening mammography. Note different screening practices: 2D (versus mostly DBT in US), double reading and longer screening interval. https://t.co/kCak2S86ph - Dr. Milch #RadAIchat
I've been thinking AI should fully write the reports, especially for low risk/ negative exams (e.g. benign calcifications, biopsy marker, post-surgical change) and the rad just opens the study, reviews, and signs. This could also apply to US, MRI, biopsies, etc. #RadAIchat
T4 There are risk percentages associated with many of the BI-RADS descriptions, it would be cool if someday these could be automatically read from our reports and calculated. OR⦠keep it simple and just edit my MRI dictations! #RadAIchat
Such a great question! I think the main key here is FEWER MARKINGS. Historical CAD had too many markings which were a distraction, and ultimately led to decreased accuracy with CAD. - Dr. Milch
https://t.co/JMESg8lLhm #RadAIchat
Dr Yala is the Mirai risk model expert, but this paper recently came out investigating some of the features it used to make decisions. https://t.co/AggWxYTwag
As the technology proves itself, mammographers may start to convert. Making sure we educate our residents about the benefits and limitations of AI would help, and ultimately explainability would be key. #RadAIchat
1/2 A big problem is that the FDA only approves AI tools that are "static" meaning they are not continually learning. A continually learning model would be more effective and more efficient. #RadAIchat
There are no prospective randomized trials demonstrating effectiveness in real-world settings, thus many practices are hesitant to adopt without high quality evidence (specifically, no trials in the US) - Milch #RadAIchat
T2 - Right now the radiologist is still responsible for the final read, so we have to trust AI and understand its strengths and weaknesses. At the same time, we need to be concerned about trusting it too much and falling into an automation bias trap.#RadAIchat
T1- Also potential for AI to assist in appropriate orders by referring physicians, streamlining patient visits, quality assessment of technologist image acquisition - Dr. Milch #RadAIchat
T1- Easy to forget that there are non-diagnostic things that would make our lives easier. Scheduling, checking on follow ups, dealing with insurance approvals. #RadAIchat
Not sure what to add to @heacockmd, but https://t.co/EBgpRqzZKy Great article that summarizes some of the existing uses for AI outside mammo. #RadAIchat
Hello! I am a breast imager from UC San Diego, and have been fascinated with AI since 2017. Excited to be part of tonight's chat as your moderator. Tonight I will also be sharing Dr. Milchβs tweets from my account. #RadAIchat
Do you forsee these technologies having an impact on the training of ED or neurosurgery residents? We think a lot about overreliance on AI in rads, could that be the case for other specialists too? #RadAIchat